CY1124202T1 - Εμβολια ανασυνδυασμενου zika - Google Patents
Εμβολια ανασυνδυασμενου zikaInfo
- Publication number
- CY1124202T1 CY1124202T1 CY20211100454T CY211100454T CY1124202T1 CY 1124202 T1 CY1124202 T1 CY 1124202T1 CY 20211100454 T CY20211100454 T CY 20211100454T CY 211100454 T CY211100454 T CY 211100454T CY 1124202 T1 CY1124202 T1 CY 1124202T1
- Authority
- CY
- Cyprus
- Prior art keywords
- zika virus
- recombinant
- immunogen
- nucleic acid
- encoding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
- B01J20/282—Porous sorbents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18441—Use of virus, viral particle or viral elements as a vector
- C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
- C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται στην παροχή συνθέσεων ανοσογόνων ή εμβολίου που περιλαμβάνουν τουλάχιστον ένα αντιγόνο ανασυνδυα σμένου ιού Zika, όπου το τουλάχιστον ένα αντιγόνο ανασυνδυασμένου ιού Zika κωδικοποιείται από τουλάχιστον μία αλληλουχία νουκλεϊνικού οξέος που κωδικοποιεί τουλάχιστον μία Ε-πρωτεΐνη ενός ιού Zika ή ένα λειτουργικό θραύσμα αυτής. Περαιτέρω παρέχονται μόρια νουκλεϊνικού οξέος και ένας ανασυνδυασμένος χιμαιρικός ιός που κωδικοποιεί και/ή περιλαμβάνει επιλεγμένα αντιγόνα από έναν ιό Zika, που είναι κατάλληλα ως συνθέσεις εμβολίου. Κατά προτίμηση, οι αλληλουχίες που κωδικοποιούν τουλάχιστον ένα αντιγόνο ιού Zika κατάλληλο για την πρόκληση μίας ανοσολογικής αντίδρασης είναι λειτουργικά συνδεδεμένες σε έναν σκελετό φορέα μη προερχόμενο από φλαβοϊό. Περαιτέρω παρέχονται μέθοδοι για τον καθαρισμό των σωματιδίων του ανασυνδυασμένου χιμαιρικού ιού ή της ανοσογόνου σύνθεσης. Τέλος, παρέχεται μία σύνθεση ανοσογόνος/εμβολίου για χρήση σε μία μέθοδο αποτροπής ή αγωγής μίας νόσου ιού Zika.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15202480.8A EP3184119A1 (en) | 2015-12-23 | 2015-12-23 | Chromatography based purification strategies for measles scaffold based viruses |
EP16162688.2A EP3184118B1 (en) | 2015-12-23 | 2016-03-29 | Recombinant zika vaccines |
PCT/EP2016/082659 WO2017109222A1 (en) | 2015-12-23 | 2016-12-23 | Recombinant zika vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124202T1 true CY1124202T1 (el) | 2022-05-27 |
Family
ID=55027478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20211100454T CY1124202T1 (el) | 2015-12-23 | 2021-05-26 | Εμβολια ανασυνδυασμενου zika |
Country Status (17)
Country | Link |
---|---|
US (2) | US11110162B2 (el) |
EP (5) | EP3184119A1 (el) |
BR (1) | BR112018012962A2 (el) |
CY (1) | CY1124202T1 (el) |
DK (1) | DK3393505T3 (el) |
ES (1) | ES2867954T3 (el) |
HR (1) | HRP20210591T1 (el) |
HU (1) | HUE054847T2 (el) |
LT (1) | LT3393505T (el) |
MX (1) | MX2018007860A (el) |
PL (1) | PL3393505T3 (el) |
PT (1) | PT3393505T (el) |
RS (1) | RS61939B1 (el) |
SG (2) | SG10202004516VA (el) |
SI (1) | SI3393505T1 (el) |
WO (2) | WO2017109222A1 (el) |
ZA (2) | ZA201804071B (el) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
US11007260B2 (en) | 2015-07-21 | 2021-05-18 | Modernatx, Inc. | Infectious disease vaccines |
EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
BR112018075513A2 (pt) * | 2016-06-13 | 2019-10-01 | Us Health | ácidos nucleicos que codificam as partículas seme-lhantes ao vírus da zika e seu uso nas vacinas e no ensaio de diagnóstico do vírus da zika |
EP3474892A1 (en) * | 2016-06-24 | 2019-05-01 | Institut Pasteur | Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases |
US11434261B2 (en) | 2016-07-27 | 2022-09-06 | Hawaii Biotech Inc. | Optimized Zika virus envelope gene and expression thereof |
GB201613191D0 (en) * | 2016-07-29 | 2016-09-14 | Univ Oxford Innovation Ltd | Zika virus vaccine |
EP3500297A1 (en) | 2016-08-16 | 2019-06-26 | Regeneron Pharmaceuticals, Inc. | Methods for quantitating individual antibodies from a mixture |
PL3532838T3 (pl) | 2016-10-25 | 2022-10-03 | Regeneron Pharmaceuticals, Inc. | Metody i systemy analizy danych chromatograficznych |
EP3582790A4 (en) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
EP3412307A1 (en) * | 2017-06-07 | 2018-12-12 | Institut Pasteur | Recombinant measles virus expressing zika virus proteins and their applications |
US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
EP3703741A1 (en) | 2017-11-03 | 2020-09-09 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
BR112020009960A2 (pt) | 2017-11-30 | 2020-11-10 | Takeda Vaccines, Inc. | método para a inativação de vírus zika e métodos relacionados |
CN107987136A (zh) * | 2017-12-13 | 2018-05-04 | 清华大学 | Zikv-ns1蛋白及其在制备寨卡病毒传播阻断疫苗中的应用 |
WO2019204654A1 (en) * | 2018-04-18 | 2019-10-24 | Utah State University | Compositions and methods for zika virus characterization and vaccine development |
EP3581646A1 (en) | 2018-06-15 | 2019-12-18 | Themis Bioscience GmbH | Integrated manufacturing and chromatographic system for virus production |
TW202005694A (zh) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
WO2020081759A1 (en) * | 2018-10-17 | 2020-04-23 | Texas Tech University System | Multivalent virus like particle vaccines |
KR101966841B1 (ko) | 2018-12-12 | 2019-04-08 | 대한민국 | 지카바이러스 e 단백질 유래의 재조합 항원 및 이의 용도 |
EP3673917A1 (en) * | 2018-12-28 | 2020-07-01 | Themis Bioscience GmbH | Norovirus vaccines |
CN109943536B (zh) * | 2019-03-26 | 2021-09-14 | 昆明理工大学 | 一种戊型肝炎病毒的培养方法及其灭活疫苗的制备方法 |
WO2020236874A1 (en) * | 2019-05-21 | 2020-11-26 | The Regents Of The University Of California | Zika virus constructs and therapeutic compositions thereof |
WO2021158815A1 (en) * | 2020-02-05 | 2021-08-12 | New York Blood Center, Inc. | Zika virus immunogenic compositions |
CN111875680A (zh) * | 2020-08-08 | 2020-11-03 | 武汉圣润生物科技有限公司 | 一种预防新型冠状病毒微颗粒的制备方法及应用 |
EP3957650A1 (en) | 2020-08-17 | 2022-02-23 | Themis Bioscience GmbH | Co-stimulatory 4-1bbl ectodomain polypeptides for immunomodulation |
CN113322282A (zh) * | 2021-04-20 | 2021-08-31 | 华南农业大学 | 稳定表达NS1蛋白的犬肾细胞系MDCK-pCDH-NS1及其构建方法和应用 |
WO2023250054A1 (en) * | 2022-06-23 | 2023-12-28 | Merck Sharp & Dohme Llc | Immunogenic compositions for epstein-barr virus proteins |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100921592B1 (ko) | 2001-06-01 | 2009-10-14 | 사노피 파스테르 바이오로직스 씨오 | 키메라 플라비바이러스 벡터 |
EP1375512B1 (en) | 2002-06-20 | 2009-07-22 | Institut Pasteur | Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions |
CA2432738A1 (en) | 2003-02-26 | 2004-08-26 | Philippe Despres | New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
FR2870126B1 (fr) | 2004-05-17 | 2009-07-17 | Pasteur Institut | Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin |
WO2007011711A2 (en) * | 2005-07-14 | 2007-01-25 | Mayo Foundation For Medical Education And Research | Paramyxoviridae virus preparations |
WO2007052163A2 (en) * | 2005-11-01 | 2007-05-10 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment |
DK1939214T3 (da) | 2006-12-22 | 2013-10-14 | Pasteur Institut | Celler og metodik til at generere ikke-segmenterede negativstrengede RNA-vira |
EP3269728B1 (en) * | 2011-10-20 | 2020-12-16 | The Government of The United States of America as represented by The Secretary, Department of Health and Human Services | Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes |
WO2013083847A2 (en) * | 2011-12-09 | 2013-06-13 | Institut Pasteur | Multiplex immuno screening assay |
EP2712871A1 (en) | 2012-09-27 | 2014-04-02 | Institut Pasteur | Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications |
US9267114B2 (en) | 2012-11-07 | 2016-02-23 | Southern Research Institute | Flavivirus envelope protein mutations affecting virion disassembly |
WO2016130786A2 (en) * | 2015-02-15 | 2016-08-18 | Integral Molecular, Inc. | Flaviviridae proteins and virions and methods of use thereof |
WO2016145149A1 (en) * | 2015-03-11 | 2016-09-15 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research | Combination purified inactivated vaccine for flaviviruses |
-
2015
- 2015-12-23 EP EP15202480.8A patent/EP3184119A1/en not_active Withdrawn
-
2016
- 2016-03-29 EP EP16162688.2A patent/EP3184118B1/en active Active
- 2016-12-23 BR BR112018012962A patent/BR112018012962A2/pt active Search and Examination
- 2016-12-23 SG SG10202004516VA patent/SG10202004516VA/en unknown
- 2016-12-23 US US16/063,239 patent/US11110162B2/en active Active
- 2016-12-23 SG SG11201804496UA patent/SG11201804496UA/en unknown
- 2016-12-23 WO PCT/EP2016/082659 patent/WO2017109222A1/en active Application Filing
- 2016-12-23 PT PT168267383T patent/PT3393505T/pt unknown
- 2016-12-23 EP EP16826738.3A patent/EP3393505B1/en active Active
- 2016-12-23 LT LTEP16826738.3T patent/LT3393505T/lt unknown
- 2016-12-23 WO PCT/EP2016/082628 patent/WO2017109211A1/en active Application Filing
- 2016-12-23 SI SI201631217T patent/SI3393505T1/sl unknown
- 2016-12-23 MX MX2018007860A patent/MX2018007860A/es unknown
- 2016-12-23 HU HUE16826738A patent/HUE054847T2/hu unknown
- 2016-12-23 US US16/063,240 patent/US10894079B2/en active Active
- 2016-12-23 DK DK16826738.3T patent/DK3393505T3/da active
- 2016-12-23 EP EP16828744.9A patent/EP3393513B1/en active Active
- 2016-12-23 ES ES16826738T patent/ES2867954T3/es active Active
- 2016-12-23 PL PL16826738T patent/PL3393505T3/pl unknown
- 2016-12-23 EP EP21165273.0A patent/EP3903814A1/en active Pending
- 2016-12-23 RS RS20210601A patent/RS61939B1/sr unknown
-
2018
- 2018-06-18 ZA ZA2018/04071A patent/ZA201804071B/en unknown
- 2018-07-16 ZA ZA2018/04735A patent/ZA201804735B/en unknown
-
2021
- 2021-04-13 HR HRP20210591TT patent/HRP20210591T1/hr unknown
- 2021-05-26 CY CY20211100454T patent/CY1124202T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP3184119A1 (en) | 2017-06-28 |
SI3393505T1 (sl) | 2021-08-31 |
EP3393505B1 (en) | 2021-03-31 |
US11110162B2 (en) | 2021-09-07 |
SG10202004516VA (en) | 2020-06-29 |
US20180371426A1 (en) | 2018-12-27 |
ES2867954T3 (es) | 2021-10-21 |
EP3393513A1 (en) | 2018-10-31 |
WO2017109222A1 (en) | 2017-06-29 |
EP3393505A1 (en) | 2018-10-31 |
WO2017109211A1 (en) | 2017-06-29 |
ZA201804071B (en) | 2020-01-29 |
SG11201804496UA (en) | 2018-07-30 |
DK3393505T3 (da) | 2021-05-10 |
MX2018007860A (es) | 2018-11-09 |
PT3393505T (pt) | 2021-04-28 |
US10894079B2 (en) | 2021-01-19 |
HUE054847T2 (hu) | 2021-10-28 |
EP3903814A1 (en) | 2021-11-03 |
PL3393505T3 (pl) | 2021-10-25 |
WO2017109211A9 (en) | 2017-07-20 |
EP3393513B1 (en) | 2021-04-21 |
BR112018012962A2 (pt) | 2018-12-04 |
EP3184118B1 (en) | 2020-05-06 |
EP3184118A1 (en) | 2017-06-28 |
ZA201804735B (en) | 2019-05-29 |
HRP20210591T1 (hr) | 2021-05-28 |
US20190083601A1 (en) | 2019-03-21 |
RS61939B1 (sr) | 2021-07-30 |
LT3393505T (lt) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124202T1 (el) | Εμβολια ανασυνδυασμενου zika | |
CY1124618T1 (el) | Ανασυνδυασμενοι hvt φορεις οι οποιοι εκφραζουν αντιγονα παθογονων των πτηνων και χρησεις αυτων | |
PH12018500199A1 (en) | Antibodies that potently neutralize hepatitis b virus and uses thereof | |
RU2019107976A (ru) | Композиция вакцины | |
DE602008000891D1 (de) | Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden | |
EA201391109A1 (ru) | Молекулы нуклеиновой кислоты, кодирующие новые антигены герпеса, вакцина, включающая их, и способы их использования | |
EA201491171A1 (ru) | Вещества, содержащие улучшенные генетические конструкции il-12, вакцины, иммунотерапевтические составы и способы их применения | |
MX2019003682A (es) | Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas. | |
PH12019500592A1 (en) | New swine influenza vaccine | |
EA202090759A2 (ru) | Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина | |
MX343830B (es) | Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma. | |
SA519401350B1 (ar) | موضع إدراج جديد لفيروس الهربس ألفا للخيول من إطار القراءة المفتوح 70 | |
CY1124707T1 (el) | Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων) | |
MX2015011487A (es) | Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas. | |
WO2014150822A3 (en) | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use | |
MX2019003156A (es) | Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika. | |
JP2018500878A5 (el) | ||
EA201990719A1 (ru) | Новые промоторы | |
MX2019007924A (es) | Vacunas contra la influenza. | |
EA202191145A1 (ru) | Вакцина виб 4/91 с гетерологичным шиповидным белком | |
RU2021109510A (ru) | Вакцинация с использованием альфа 3 домена mica/b для лечения рака | |
EA202191147A1 (ru) | Вакцина виб h52 с гетерологичным шиповидным белком | |
EA201270794A1 (ru) | Маркерная вакцина против классической чумы свиней | |
EA201892526A1 (ru) | Консенсусные антигены филовируса, конструкции нуклеиновых кислот и вакцины, полученные на их основе, и способы их применения | |
AR107057A1 (es) | Antígenos del virus de la inmunodeficiencia humana, vectores, composiciones y métodos de uso de estos |